Polaryx Therapeutics (NASDAQ:PLYX) Announces Quarterly Earnings Results

Polaryx Therapeutics (NASDAQ:PLYX – Get Free Report) released its earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.02, FiscalAI reports.

Polaryx Therapeutics Stock Down 0.6%

Shares of NASDAQ PLYX traded down $0.01 on Friday, reaching $2.48. 104,035 shares of the company traded hands, compared to its average volume of 946,525. Polaryx Therapeutics has a fifty-two week low of $1.86 and a fifty-two week high of $48.91. The firm’s 50 day moving average is $2.33. The company has a market capitalization of $123.88 million and a PE ratio of -49.68.

Get Polaryx Therapeutics alerts:

Insider Activity at Polaryx Therapeutics

In other news, CEO Alex Keun Mo Yang acquired 88,453 shares of Polaryx Therapeutics stock in a transaction dated Wednesday, May 27th. The shares were acquired at an average cost of $4.07 per share, with a total value of $360,003.71. Following the purchase, the chief executive officer directly owned 24,233,249 shares of the company’s stock, valued at approximately $98,629,323.43. This trade represents a 0.37% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 45.82% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

PLYX has been the topic of a number of research analyst reports. Raymond James Financial assumed coverage on shares of Polaryx Therapeutics in a report on Thursday. They set a “strong-buy” rating and a $6.00 price objective on the stock. HC Wainwright initiated coverage on shares of Polaryx Therapeutics in a report on Thursday, July 9th. They issued a “buy” rating and a $7.00 price target on the stock. Zacks Research upgraded shares of Polaryx Therapeutics to a “hold” rating in a research note on Friday, July 10th. Wall Street Zen downgraded shares of Polaryx Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Finally, Weiss Ratings upgraded shares of Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $7.67.

Read Our Latest Stock Analysis on Polaryx Therapeutics

About Polaryx Therapeutics

(Get Free Report)

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

Featured Articles

• Five stocks we like better than Polaryx Therapeutics
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?

Receive News & Ratings for Polaryx Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polaryx Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.